Abstract

Hepatitis C continues to present challenges despite the introduction of directly act-ing antiviral (DAA) treatments. While DAAs have revolutionized the treatment of hepatitis C by offering high cure rates with fewer side effects, there are still several ongoing challenges. Firstly, identifying and diagnosing individuals with hepatitis C remains a significant barrier. Many people with hepatitis C are unaware of their status, leading to delayed diagnosis and treatment initiation. Additionally, certain populations, such as marginalized communities and people who inject drugs, face barriers to accessing testing and treatment services. Secondly, treatment access and affordability are persistent issues. Although DAAs have been hailed for their efficacy, their high costs limit accessibility for many individuals, particularly in low- and middle-income countries. This highlights the need for continued efforts to improve drug affordability and expand access to treatment globally. Thirdly, addressing co-infections and comorbidities is an ongoing challenge in hepatitis C management. Many individuals with hepatitis C also have coexisting conditions, such as HIV or liver cirrhosis, requiring integrated care approaches to effectively manage these complex health needs. Furthermore, despite the effectiveness of DAAs, reinfection remains a concern, especially among high-risk popula-tions. This emphasizes the importance of comprehensive prevention strategies and ongoing monitoring to prevent recurrent infections. Therefore, while the advent of DAAs has trans-formed the landscape of hepatitis C treatment, continued efforts are necessary to address the challenges of diagnosis, treatment access, co-infections, and reinfection. A comprehensive approach that integrates testing, treatment, and support services is essential to achieve the goal of hepatitis C elimination.

Keywords: Hepatitis C, directly acting antiviral, marginalized communities, liver cirrhosis, hepatocellular carcinoma.